Among non‐GCB‐type DLBCL cases, about 30%46, 47, 48, 49 harbor MYD88 mutations, which induce the activation of NF‐κβ and JAK/STAT pathways and cause PD‐L1 overexpression.46, 50. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.